证券代码：002644 证券简称：佛慈制药 公告编号：2024-015 兰州佛慈制药股份有限公司 第七届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 兰州佛慈制药股份有限公司（以下简称"公司"）第七届董事会第二十七次会 议于 2024 年 4 月 30 日下午 15：30 以现场会议方式召开，会议由公司半数以上 董事共同推举董事单小东先生主持。会议通知于 2024 年 4 月 19 日以书面、电子 邮件、电话等方式送达。会议应出席董事 7 人，实际出席董事 7 人。公司监事会 成员、高级管理人员列席会议。本次会议的召开符合《公司法》《公司章程》《董 事会议事规则》及有关法律、法规的规定。 与会董事经过审议，通过以下议案： 一、审议通过了《关于选举董事长的议案》 《关于选举董事长暨补选董事会专门委员会委员的公告》详见《证券时报》 《证券日报》及巨潮资讯网(www.cninfo.com.cn）。 表决结果：7 票同意，0 票反对，0 票弃权。 二、审议通过了《关于补选董事会专门委员会委员的议案》 《关于选举董事长暨补选董事会专门委员 ...

北京德恒（兰州）律师事务所 关于兰州佛慈制药股份有限公司 二〇二三年年度股东大会的 法律意见 甘肃省兰州市城关区雁园路 601 号甘肃省商会大厦 A 座 15 层 电话：（0931）8260111 邮编：730030 北京德恒（兰州）律师事务所 关于兰州佛慈制药股份有限公司 二〇二三年年度股东大会的法律意见 北京德恒（兰州）律师事务所 关于兰州佛慈制药股份有限公司 二〇二三年年度股东大会的 法律意见 德恒 37G20230065- 00004 号 北京德恒（兰州）律师事务所（以下简称：本所）受兰州佛慈制药股份有限 公司（以下简称：公司/贵公司）委托，就贵公司 2023 年年度股东大会（以下简 称：本次股东大会）召开的有关事宜，根据《中华人民共和国公司法》（以下简 称：《公司法》）、《上市公司股东大会规则》（以下简称：《股东大会规则》）、《兰 州佛慈制药股份有限公司章程》（以下简称：《公司章程》）的有关规定，本所律 师就本次会议的召集、召开程序、现场出席会议人员资格、表决程序等相关事项 进行见证，并发表本《法律意见》。 为出具本《法律意见》，本所律师出席了本次会议，并审查了贵公司提供的 以下文件，包括但不限于： ...

证券代码：002644 证券简称：佛慈制药 公告编号：2024-014 兰州佛慈制药股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 1.本次股东大会无增加、变更、否决议案的情形； 2.本次股东大会不涉及变更前次股东大会决议。 一、会议召开情况和出席情况 1.会议召开情况 （1）会议召集人：公司董事会； （2）会议主持人：公司董事王新海先生（由半数以上董事共同推举）； （3）现场会议召开时间：2024 年 4 月 30 日（星期二）14：00 （4）现场会议召开地点：甘肃省兰州市兰州新区华山路 2289 号公司五楼会 议室； （5）会议召开方式：本次会议采用现场投票与网络投票表决相结合方式； （6）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2024 年 4 月 30 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券 交易所互联网投票系统进行网络投票的时间为 2024 年 4 月 30 日上午 9:15 至下 午 15:00 期间的任意时间； ...

华龙证券股份有限公司 关于 甘肃省国有资产投资集团有限公司要约收购 兰州佛慈制药股份有限公司 之 2024 年第一季度持续督导意见 二〇二四年四月 华龙证券股份有限公司 关于甘肃省国有资产投资集团有限公司要约收购兰州佛慈 制药股份有限公司之 2024 年第一季度持续督导意见 华龙证券股份有限公司（以下简称"本财务顾问"、"华龙证券"）接受收购人 甘肃省国有资产投资集团有限公司（以下简称"甘肃国投"、"收购人"）委托担任 其收购兰州佛慈制药股份有限公司（以下简称"佛慈制药"、"上市公司"）之财务 顾问（上述收购行为以下简称"本次收购"），依照《上市公司收购管理办法》（以 下简称"收购管理办法"）和《上市公司并购重组财务顾问业务管理办法》，持续 督导期从公告收购报告书至收购完成后的 12 个月止。 本财务顾问出具 2024 年第一季度（2024 年 1 月 1 日至 2024 年 3 月 31 日）， （以下简称"本持续督导期"）的持续督导意见（以下简称"本意见"）。 一、本次交易情况 本次要约收购系甘肃国投通过购买兰州佛慈医药产业发展集团有限公司（以 下简称"佛慈集团"）100%股权的方式成为其控股股东。佛慈集 ...

华龙证券股份有限公司 关于 甘肃省国有资产投资集团有限公司要约收购 兰州佛慈制药股份有限公司 之 2023 年度持续督导意见 财务顾问 二〇二四年四月 财务顾问声明 本次要约收购系甘肃国投通过购买兰州佛慈医药产业发展集团有限公司（以 下简称"佛慈集团"）100%股权的方式成为其控股股东。佛慈集团为上市公司佛 慈制药的控股股东，持有上市公司已发行股份的 61.63%。本次交易完成后，甘 肃国投通过佛慈集团间接拥有佛慈制药的权益将超过佛慈制药已发行股份的 30%，从而触发全面要约收购义务。因此，根据《证券法》和《收购管理办法》， 甘肃国投应当向佛慈制药除佛慈集团之外的其他所有持有上市流通普通股（A 股） 的股东发出全面要约。 本持续督导意见不构成对佛慈制药的任何投资建议，对投资者根据本持续督 导意见所作出的任何投资决策可能产生的风险，本财务顾问不承担任何责任。本 持续督导意见根据佛慈制药及甘肃国投提供的相关材料编制，佛慈制药及甘肃国 投保证提供的为出具本持续督导意见所依据的所有文件和材料真实、准确、完整、 及时，不存在虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性、完整 性和及时性负责。本财务顾问提醒投资人 ...

证券代码：002644 证券简称：佛慈制药 公告编号：2024-013 关于举行 2023 年度暨 2024 年第一季度网上业绩说明会的公告 特此公告。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 兰州佛慈制药股份有限公司董事会 兰州佛慈制药股份有限公司（以下简称"公司"）已于 2024 年 4 月 10 日披露 了《2023 年年度报告》以及《2024 年第一季度报告》。为方便广大投资者更深入 全面地了解公司 2023 年年度以及 2024 年第一季度经营情况，公司将于 2024 年 4 月 17 日（星期三）15:00——17:00 在全景网举办 2023 年度暨 2024 年第一季度 网上业绩说明会。本次业绩说明会将采用网络远程的方式举行，投资者可登陆全 景网"投资者关系互动平台"（https://ir.p5w.net）参与本次业绩说明会。 出席本次说明会的人员有：公司董事、副总经理王迎春先生，独立董事龙凤 鸣女士，副总经理冯晓云先生，董事会秘书王军辉先生，财务总监岳金风女士。 为充分尊重投资者、提升交流的针对性，现就公司 2023 年度暨 2024 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥274,329,503.97, representing a decrease of 13.85% compared to ¥307,394,758.83 in the same period last year[5] - Net profit attributable to shareholders was ¥18,387,224.27, down 23.11% from ¥27,454,528.98 year-over-year[5] - Basic and diluted earnings per share decreased by 23.08% to ¥0.0360 from ¥0.0538 in the same period last year[5] - Net profit for Q1 2024 was CNY 18,641,576.17, representing a decline of 21.93% from CNY 23,903,831.70 in Q1 2023[19] - Total operating revenue for Q1 2024 was CNY 274,329,503.97, a decrease of 13.83% compared to CNY 318,446,773.30 in Q1 2023[18] Cash Flow - The net cash flow from operating activities was -¥16,074,451.17, a significant decline of 306.33% compared to -¥3,956,040.69 in the previous year[11] - The company's cash flow from operating activities showed a significant improvement, with a net cash inflow of CNY 22,999,318.64 in Q1 2024 compared to CNY 30,151,744.30 in Q1 2023[19] - Total cash inflow from operating activities is 179,828,915.87 yuan, down 35.4% from 277,840,595.03 yuan in the previous period[21] - Cash outflow from operating activities is 195,903,367.04 yuan, a decrease of 30.5% compared to 281,796,635.72 yuan in the previous period[21] - The cash flow from operating activities has shown a concerning trend with a net outflow, which may impact future liquidity[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,527,502,345.91, a slight decrease of 0.02% from ¥2,528,102,214.36 at the end of the previous year[5] - Total liabilities decreased to CNY 740,430,835.25 in Q1 2024 from CNY 759,672,279.87 in Q1 2023, reflecting a reduction of 2.93%[17] - The company's cash and cash equivalents decreased to ¥365,338,610.71 from ¥406,040,604.70 at the beginning of the period, a decline of approximately 10.5%[15] - Total current assets amounted to ¥1,252,844,935.25, up from ¥1,238,869,322.84, reflecting a growth of about 1.1%[15] Investment and Expenses - Investment income showed a significant decline of 525.78%, resulting in a loss of -¥2,609,200.00 compared to a profit of ¥612,806.13 in the previous year[10] - Financial expenses decreased by 58.87% to -¥446,907.81, primarily due to adjustments in bank deposit interest rates[10] - Research and development expenses for Q1 2024 were CNY 6,885,069.00, an increase from CNY 6,295,170.51 in the previous year, indicating a focus on innovation[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,759[13] - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group, holds 61.63% of the shares, totaling 314,713,676 shares[13] - The total equity attributable to shareholders of the parent company increased to CNY 1,763,758,032.04 in Q1 2024 from CNY 1,745,370,807.77 in Q1 2023, reflecting a growth of 1.05%[17] Other Information - The company has not disclosed any new product developments or technological advancements in the current report[14] - There are no significant changes in the top 10 shareholders' participation in margin trading or securities lending[14] - The company has not reported any mergers or acquisitions during this period[14] - No new strategic initiatives have been mentioned in the current financial report[14] - The first quarter report has not been audited, which may affect the reliability of the financial data presented[23]

Financial Performance - The company reported a total revenue of 510.657 million RMB for the year 2023, with a cash dividend of 0.30 RMB per 10 shares proposed for distribution to shareholders [5]. - The company's operating revenue for 2023 was CNY 1,163,134,031, representing an increase of 11.58% compared to CNY 1,042,388,830 in 2022 [21]. - The net profit attributable to shareholders decreased by 38.16% to CNY 67,189,706.9 from CNY 108,654,174 in the previous year [21]. - The basic earnings per share dropped to CNY 0.1316, down 38.16% from CNY 0.2128 in 2022 [21]. - The company achieved total operating revenue of 1,163.13 million yuan in 2023, representing a year-on-year growth of 11.58% [39]. - The net profit attributable to shareholders of the listed company was 67.19 million yuan, a year-on-year decrease of 38.16% [39]. - The company reported a total of CNY 16,251,899.37 in non-recurring gains for 2023, significantly lower than CNY 53,545,123.25 in 2022 [28]. - The company experienced a quarterly revenue decline in Q4 2023, with revenue of CNY 228,278,130.43 compared to CNY 268,947,825.53 in Q3 2023 [26]. - The weighted average return on net assets for 2023 was 3.83%, down from 6.50% in 2022 [21]. - The company reported a total revenue of 1.2 billion CNY for the fiscal year 2023, representing a year-over-year increase of 15% [115]. Operational Stability and Governance - The company has not changed its main business since its listing, indicating stability in its operational focus [20]. - The board of directors has confirmed that all financial reports are true, accurate, and complete, ensuring accountability for the information presented [5]. - The company has implemented a comprehensive governance reform to enhance its operational efficiency and risk management capabilities [46]. - The company maintains independence from its controlling shareholder in business operations, personnel, assets, and finances, ensuring a self-sufficient operational framework [108]. - The company has established a governance structure to prevent any institutional confusion with other controlled enterprises [160]. - The company has committed to compliance with applicable laws and regulations in managing potential competition with its controlling shareholder's enterprises [111]. Research and Development - The company is actively enhancing its research and development capabilities through collaborations with universities and research institutions [37]. - The company has established 7 research and development platforms, including 3 national-level platforms, enhancing its innovation capabilities [45]. - The company is focusing on developing health food products that leverage local medicinal resources, aiming to enhance the value of its offerings and contribute to regional economic development [66]. - The company is committed to increasing R&D investment to support the development of new traditional Chinese medicine products and improve its core competitiveness [96]. - The company is conducting research for over 100 products to meet Hong Kong registration standards, aiming to enhance its product reputation and market presence [66]. Market Expansion and Sales Strategy - The company has adopted a diversified sales model, combining distributor sales, direct supply to chain pharmacies, and bidding for basic medical insurance products [38]. - The company achieved over 100 million in sales in both Guangdong and international markets, marking a strategic goal of reaching billion-level markets outside Gansu and Shaanxi [44]. - The company is focusing on strengthening its brand and increasing market influence through participation in major industry exhibitions and promotional activities [85]. - The company plans to enhance its market expansion and product development, aiming for breakthroughs in over CNY 100 million market, single product, and customer segments [83]. - The company is expanding its market presence in the southwestern region of China, targeting a 25% increase in market share by the end of 2024 [116]. Environmental and Social Responsibility - The company has been recognized as a national-level green factory and a provincial-level green factory, emphasizing its focus on sustainable development [40]. - The company has engaged in poverty alleviation efforts, employing nearly 100 local farmers through medicinal herb processing projects and providing training to over 2,000 households in mountainous areas to enhance their income [156]. - The company has established a comprehensive environmental management system, achieving ISO 14001:2015 and ISO 45001:2018 certifications, and has not faced any significant environmental pollution incidents during the reporting period [151]. - The company has implemented measures to reduce carbon emissions, including replacing coal-fired boilers with natural gas heating systems, resulting in significant energy savings and a transition to low-pollution, high-efficiency operations [150]. Financial Management and Internal Control - The company has established an internal audit system to oversee compliance and the integrity of financial information, enhancing accountability [106]. - The internal control system has been continuously improved, with 100% of the total assets and operating income of the units included in the evaluation scope accounted for in the company's consolidated financial statements [144]. - The internal control audit report issued by the accounting firm provided a standard unqualified opinion, confirming effective internal control over financial reporting as of December 31, 2023 [146]. - The company has implemented a performance evaluation and incentive mechanism for its management team to enhance operational efficiency [106]. - The company has committed to maintaining a complete and independent labor, personnel, and compensation management system [159]. Shareholder Engagement and Dividends - The company distributed cash dividends of 0.50 yuan per 10 shares, totaling 25,532,850 yuan, based on a total share capital of 510,657,000 shares as of December 31, 2022 [139]. - The company plans to distribute cash dividends of 0.30 yuan per 10 shares, amounting to 15,319,710 yuan, based on the same total share capital for the 2023 fiscal year [140]. - The company ensures the independence of its financial personnel, prohibiting them from holding positions in other enterprises controlled by the company [159]. - The company has ensured that minority shareholders have the opportunity to express their opinions and that their rights are protected during the dividend distribution process [140]. Strategic Acquisitions and Partnerships - The company completed the acquisition of 60% equity in Guangdong Foci Puzhe Pharmaceutical Co., Ltd. to enhance market expansion and improve overall profitability [143]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach [118]. - The company plans to acquire 60% equity in Guangdong Foci Pharmaceutical Co., Ltd. for a transfer price of 1,545 million RMB, based on an assessed value of 2,575 million RMB [177]. - The acquisition is expected to enhance the company's market presence in South China, aiming for a market breakthrough exceeding 1 billion RMB and improving overall profitability [178].

兰州佛慈制药股份有限公司 独立董事 2023 年度述职报告 作为兰州佛慈制药股份有限公司（以下简称"公司"）第七届董事会独立董 事，2023 年度本人严格按照《公司法》《证券法》《上市公司独立董事管理办 法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》等有关法律法规，以及《公司章程》《独立董事工作制度》的相关规定， 本着独立、客观的原则，恪尽职守，勤勉尽责，充分行使独立董事的职权，维 护公司及全体股东尤其是中小股东的利益。现将本人 2023 年度履行职责的情况 汇报如下： 一、基本情况 2023 年度，公司召开了 6 次董事会和 2 次股东大会，本人均按时出席，未 有无故缺席的情况发生。具体如下： | 本报告期 | 现场出席 | 以通讯方 | 委托出席 | 是否连续 缺席董事 | 两次未亲 | | | --- | --- | --- | --- | --- | --- | --- | | 应参加董 | 董事会次 | 式参加董 | 董事会次 | | | 出席股东 | | 事会次数 | 数 | 事会次数 | 数 | 会次数 | 自参加董 | 大会次数 | | | | | | | 事会 ...

兰州佛慈制药股份有限公司 2023 年度监事会工作报告 2023年度，兰州佛慈制药股份有限公司（以下简称"公司"）监事会依照《公 司法》《证券法》《深圳证券交易所股票上市规则》等法律法规以及《公司章程》 《监事会议事规则》，本着对全体股东负责的态度，恪尽职守、勤勉尽责，依法 独立行使职权，对公司的生产经营情况、依法运作情况、财务状况以及内控管理 制度、董事和高级管理人员履职情况等进行了监督和核查，切实维护了公司和股 东的合法权益。现将监事会2023年度的主要工作报告如下： 一、监事会会议召开情况 2023 年，公司召开监事会会议 4 次，会议的召集、召开和决策程序均符合 《公司法》《公司章程》《监事会议事规则》等法律法规和规章制度规定，未发生 否决议案的情形，各次会议情况如下： | 序号 | 召开时间 | | 会议届次 | 召开方式 | 审议事项 | | --- | --- | --- | --- | --- | --- | | 1 | 2023 年 月 日 3 | 29 | 第七届监事会 第十七次会议 | 现场会议 | 1.《2022 年度监事会工作报告》 | | | | | | | 2.《2022 年度财 ...